A Better Life For Patients With Rare Diseases

Latest News & Press Releases

ACERAGEN

Our Vision

Aceragen is a rare disease biopharmaceutical company. We take on rare, orphan diseases that typically have no approved treatments, and to develop important therapies to help patients. The needs of patients who suffer from under-served rare diseases drive our mission.

Learn More

Patient Info

The needs of patients who suffer from unserved or under-served rare diseases drive our mission at Aceragen

Learn More

Latest News

The Cystic Fibrosis Foundation has awarded up to $3.5 million to Aceragen to support the clinical development of ACG-701, an investigational antibiotic to treat pulmonary exacerbations in people with cystic...

Agreement supports late-stage clinical study for ACG-701 beginning in 2022 Advances Aceragen’s development effort to treat life-threatening rare and orphan diseases RALEIGH-DURHAM, NC – January 06, 2022 - Aceragen, Inc.,...